Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Well-differentiated gastroenteropancreatic and lung neuroendocrine tumors are generally
malignancies with a prolonged natural history. However, clinical behavior is heterogeneous
and when tumor progression is observed, treatment options are limited. The most used therapy
for neuroendocrine tumors management are somatostatin analogs. However, even the use in lung
carcinoids is quite usual, no antitumoral activity has been demonstrated. Tremelimumab and
Durvalumab combination could be more efficient drugs to improve immune system activation and
could obtain a significantly higher clinical benefit in these patients. Tremelimumab and
Durvalumab would be the first immune combination agents showing efficacy in neuroendocrine
neoplasms of different origins.